Mesoblast Limited and Lonza Signed an Agreement for commercial manufacture of remestemcel-L

  • Oct 17, 2019 AEDT
  • Team Kalkine

Leading developer of allogeneic cellular medicines Mesoblast Limited (ASX: MSB) has struck a deal with Lonza for commercial manufacture of Mesoblast’s lead allogeneic (off-the-shelf) cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease (aGVHD).

  • The agreement between Mesoblast and Lonza will facilitate inventory build ahead of the planned United States (US) market launch of remestemcel-L;
  • Mesoblast expects to complete filing of the rolling Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) by the end 2019;

By AEST 1:18 PM, MSB’s stock was trading at $1.845, up by 3.361% relative to previous close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK